no comments

Goodman & Gilman’s – The Pharmacological Basis of Therapeutics 13th Edition


The Pharmacological Basis of Therapeutics
The first edition of this book appeared in 1941, the product of a collaboration between two friends and professors at Yale, Louis Goodman and Alfred Gilman. Their purpose, stated in the preface to that edition, was to correlate pharmacology with related medical sciences, to reinterpret the actions and uses of drugs in light of advances in medicine and the basic biomedical sciences, to emphasize the applications of pharmacodynamics to therapeutics, and to create a book that would be useful to students of pharmacology and to physicians. We continue to follow these principles in the 13th edition.
The 1st edition was quite successful despite its high price, $12.50, and soon became known as the “blue bible of pharmacology.” The book was evidence of the deep friendship between its authors, and when the Gilmans’ son was born in 1941, he was named Alfred Goodman Gilman. World War II and the relocation of both authors—Goodman to Utah, Gilman to Columbia—postponed a second edition until 1955. The experience of writing the second edition during a period of accelerating basic research and drug development persuaded the authors to become editors, relying on experts whose scholarship they trusted to contribute individual chapters, a pattern that has been followed ever since.
Alfred G. Gilman, the son, served as an associate editor for the 5th edition (1975), became the principal editor for the 6th (1980), 7th (1985), and 8th (1990) editions, and consulting editor for the 9th and 10th editions that were edited by Lee Limbird and Joel Hardman. After an absence in the 11th edition, Al Gilman agreed to co-author the introductory chapter in the 12th edition. His final contribution to G&G, a revision of that chapter, is the first chapter in this edition, which we dedicate to his memory.
A multi-authored text of this sort grows by accretion, posing challenges to editors but also offering 75 years of wisdom, memorable pearls, and flashes of wit. Portions of prior editions persist in the current edition, and we have given credit to recent former contributors at the end of each chapter. Such a text also tends to grow in length with each edition, as contributors add to existing text and as pharmacotherapy advances.
To keep the length manageable and in a single volume, Dr. Randa Hilal-Dandan and I prepared a shortened version of each chapter and then invited contributors to add back old material that was essential and to add new material. We also elected to discard the use of extract (very small) type and to use more figures to explain signaling pathways and mechanisms of drug action. Not wanting to favor one company’s preparation of an agent over that of another, we have ceased to use trade names except as needed to refer to drug combinations or to distinguish multiple formulations of the same agent with distinctive pharmacokinetic or pharmacodynamic properties. Counter-balancing this shortening are five new chapters that reflect advances in the therapeutic manipulation of the immune system, the treatment of viral hepatitis, and the pharmacotherapy of cardiovascular disease and pulmonary artery hypertension.

Descargar PDF


  • Contributors
  • Preface
  • Acknowledgments
Section I: General Principles
  • 1. Drug Invention and the Pharmaceutical Industry
  • 2. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination
  • 3. Pharmacodynamics: Molecular Mechanisms of Drug Action
  • 4. Drug Toxicity and Poisoning
  • 5. Membrane Transporters and Drug Response
  • 6. Drug Metabolism
  • 7. Pharmacogenetics
Section II: Neuropharmacology
  • 8. Neurotransmission: The Autonomic and Somatic Motor Nervous Systems
  • 9. Muscarinic Receptor Agonists and Antagonists
  • 10. Anticholinesterase Agents
  • 11. Nicotine and Agents Acting at the Neuromuscular Junction and Autonomic Ganglia
  • 12. Adrenergic Agonists and Antagonists
  • 13. 5-Hydroxytryptamine (Serotonin) and Dopamine
  • 14. Neurotransmission in the Central Nervous System
  • 15. Drug Therapy of Depression and Anxiety Disorders
  • 16. Pharmacotherapy of Psychosis and Mania
  • 17. Pharmacotherapy of the Epilepsies
  • 18. Treatment of Central Nervous System Degenerative Disorders
  • 19. Hypnotics and Sedatives
  • 20. Opioids, Analgesia, and Pain Management
  • 21. General Anesthetics and Therapeutic Gases
  • 22. Local Anesthetics
  • 23. Ethanol
  • 24. Drug Use Disorders and Addiction
Section III: Modulation of Pulmonary, Renal, and Cardiovascular Function
  • 25. Drugs Affecting Renal Excretory Function
  • 26. Renin and Angiotensin
  • 27. Treatment of Ischemic Heart Disease
  • 28. Treatment of Hypertension
  • 29. Therapy of Heart Failure
  • 30. Antiarrhythmic Drugs
  • 31. Treatment of Pulmonary Arterial Hypertension
  • 32. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs
  • 33. Drug Therapy for Dyslipidemias
Section IV: Inflammation, Immunomodulation, and Hematopoiesis
  • 34. Introduction to Immunity and Inflammation
  • 35. Immunosuppressants and Tolerogens
  • 36. Immune Globulins and Vaccines
  • 37. Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor
  • 38. Pharmacotherapy of Inflammation, Fever, Pain, and Gout
  • 39. Histamine, Bradykinin, and Their Antagonists.
  • 40. Pulmonary Pharmacology
  • 41. Hematopoietic Agents: Growth Factors, Minerals, and Vitamins
  • Section V: Hormones and Hormone Antagonists
  • 42. Introduction to Endocrinology: The Hypothalamic-Pituitary Axis
  • 43. Thyroid and Antithyroid Drugs
  • 44. Estrogens, Progestins, and the Female Reproductive Tract
  • 45. Androgens and the Male Reproductive Tract
  • 46. Adrenocorticotropic Hormone, Adrenal Steroids, and the Adrenal Cortex
  • 47. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia
  • 48. Agents Affecting Mineral Ion Homeostasis and Bone Turnover
Section VI: Gastrointestinal Pharmacology
  • 49. Pharmacotherapy for Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease
  • 50. Gastrointestinal Motility and Water Flux, Emesis, and Biliary and Pancreatic Disease
  • 51. Pharmacotherapy of Inflammatory Bowel Disease
  • Section VII: Chemotherapy of Infectious Diseases
  • 52. General Principles of Antimicrobial Therapy.
  • 53. Chemotherapy of Malaria
  • 54. Chemotherapy of Protozoal Infections: Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, Leishmaniasis, and Other Protozoal Infections
  • 55. Chemotherapy of Helminth Infections
  • 56. Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections
  • 57. Penicillins, Cephalosporins, and Other β-Lactam Antibiotics
  • 58. Aminoglycosides.
  • 59. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents
  • 60. Chemotherapy of Tuberculosis, Mycobacterium avium Complex Disease, and Leprosy
  • 61. Antifungal Agents
  • 62. Antiviral Agents (Nonretroviral)
  • 63. Treatment of Viral Hepatitis (HBV/HCV)
  • 64. Antiretroviral Agents and Treatment of HIV Infection
Section VIII: Pharmacotherapy of Neoplastic Disease
  • 65. General Principles in the Pharmacotherapy of Cancer
  • 66. Cytotoxic Drugs
  • 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules
  • 68. Hormones and Related Agents in the Therapy of Cancer
Section IX: Special Systems Pharmacology
  • 69. Ocular Pharmacology
  • 70. Dermatological Pharmacology
  • 71. Environmental Toxicology: Carcinogens and Heavy Metals
  • Appendices
  • I. Principles of Prescription Order Writing and Patient Compliance
  • II. Design and Optimization of Dosage Regimens: Pharmacokinetic Data
  • Index
Anatomia Biologia Cardiologia Cirugia Enfermeria Farmacología Fisiología Ginecología Odontologia Oncología Otros Pediatría Psicología
Contemporary Implant Dentistry 1st edition – Carl E. Misch
Atlas de Anatomía Humana 5ª Edición – Johannes W. Rohen
PhysioEx 9.0: Simulaciones de laboratorio de fisiología